SGM-101
Phase 3Small molecule
SGM-101 is one of 74 small molecule programs targeting Adenocarcinoma. It is currently in Phase 3.
2
Indications
7
Total Trials
2
Active Trials
73
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
949 competitors in Colorectal Cancer
#DrugCompanyPhaseTrials
1SGM-101
LLeiden University Medical Center
Phase 3
Eylea
RegeneronPreclinical
PORTRAZZA
Eli LillyPreclinical
Emend IV
Merck & Co.Preclinical
Ketalar
AAultman Health Foundation
Preclinical
Ultiva
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Bridion
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Gas-X
PPortuguese Oncology Institute, Coimbra
Preclinical
Andriol
AAuxilium
Preclinical
Versed
CConrado Roberto Hoffmann Filho
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Colorectal Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SGM-101. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- LLeiden University Medical Center